Nicholas Saraceno, Editor

Current production of Qdenga will increase to 50 million doses a year.

A cohort study explores the association of Medicare Advantage enrollment with post-acute care use, along with patient outcomes among retired state employees.

The company’s cloud technology services aim to assist healthcare and pharma with AI integration.

A cross-sectional study investigates how this supply chain link helps increase Medicare Part D spending on self-administered specialty drugs.

The CRO’s FortreaRx doubles in size, including a boost in cold chain storage, while also continuing to improve its patient access services.

The annual report published by IQVIA examines movement surrounding drug launches and new clinical trials, during the post-pandemic era.

A cohort study investigates how a change in clinical guidelines, an expanded label, and reduction in drug prices can impact the use of PCSK9 inhibitors as a treatment for atherosclerotic cardiovascular disease.

OneScan 7.1 is expected to boost compliance, while also improving pharma supply chain efficiencies.

A trial set out to determine whether empagliflozin can help prevent hospitalizations and extend life for patients with heart failure, while not hurting the US payers’ pockets.

Phase III results from Keytruda (pembrolizumab)’s NRG-GY018 trial help influence the agency’s decision.

Arshad M. Khanani, MD, MA, FASRS, will help lead development efforts for sozinibercept, a potential wet AMD treatment.

As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications.

The agency will make its final decision surrounding the locally advanced or metastatic nonsquamous NSCLC drug —based on results from the TROPION-Lung01 Phase III trial—by Q4 2024.

The partnership revolves around meeting various agency standards and industry requirements pertaining to the drug development and manufacturing lifecycle.

The new seals include sustainable film material containing recyclate content of up to 90%.

The financial commitment features construction of new warehouses in Pennsylvania and North Carolina.

Scientists develop algorithms that can not only identify tumors that will respond well to chemotherapy, but which are also likely to resist treatment.

Analysis explores where drug prices are derived from, and whether a holistic societal approach can help determine these products’ true value.

Examination evaluates investigational stem cell interventions, including how the states have implemented their own policies when it comes to their uses.

Cohort study explores value-based insurance designs, while also determining how one’s place of residency can potentially play a role.

Researchers explore the proportion of approved drugs in the Canadian marketplace that utilize manufacturer-sponsored patient support programs, along with the types of medications that are more likely to do so.

Investigators examine the validity of phosphodiesterase type 5 inhibitors for erectile dysfunction, such as Viagra, being repurposed for the treatment of Alzheimer's disease.

A study investigates the effectiveness of bivalent mRNA COVID-19 vaccines against the Omicron variant among participants 5-17 years of age.

Trial for the treatment of ATTR-CM demonstrated an 81% absolute survival rate, along with an observed mean annual CVH frequency of 0.29.

Cohort study dives into whether low income subsidy losses are associated with disability status, age, and race and ethnicity.

A cohort study investigates the impact of Senate Bill 2994A and answers the question: does the repeal of school-entry nonmedical vaccination exemptions result in a rise in school vaccinations?

Pharma Commerce's new style is built off of the back of our new and improved editorial calendar.

Pharma Commerce travels to Orlando for a pulse-check on this fast-evolving landscape in patient care.

An analysis conducted by RAND Corporation determines that majority of new Rx medications are first sold in the United States before making their debut in other countries.

A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending.